Daily Sabah logo

Politics
Diplomacy Legislation War On Terror EU Affairs Elections News Analysis
TÜRKİYE
Istanbul Education Investigations Minorities Expat Corner Diaspora
World
Mid-East Europe Americas Asia Pacific Africa Syrian Crisis Islamophobia
Business
Automotive Economy Energy Finance Tourism Tech Defense Transportation News Analysis
Lifestyle
Health Environment Travel Food Fashion Science Religion History Feature Expat Corner
Arts
Cinema Music Events Portrait Reviews Performing Arts
Sports
Football Basketball Motorsports Tennis
Opinion
Columns Op-Ed Reader's Corner Editorial
PHOTO GALLERY
JOBS ABOUT US RSS PRIVACY CONTACT US
© Turkuvaz Haberleşme ve Yayıncılık 2023

Daily Sabah logo

عربي
  • Politics
    • Diplomacy
    • Legislation
    • War On Terror
    • EU Affairs
    • Elections
    • News Analysis
  • TÜRKİYE
    • Istanbul
    • Education
    • Investigations
    • Minorities
    • Expat Corner
    • Diaspora
  • World
    • Mid-East
    • Europe
    • Americas
    • Asia Pacific
    • Africa
    • Syrian Crisis
    • Islamophobia
  • Business
    • Automotive
    • Economy
    • Energy
    • Finance
    • Tourism
    • Tech
    • Defense
    • Transportation
    • News Analysis
  • Lifestyle
    • Health
    • Environment
    • Travel
    • Food
    • Fashion
    • Science
    • Religion
    • History
    • Feature
    • Expat Corner
  • Arts
    • Cinema
    • Music
    • Events
    • Portrait
    • Reviews
    • Performing Arts
  • Sports
    • Football
    • Basketball
    • Motorsports
    • Tennis
  • Gallery
  • Opinion
    • Columns
    • Op-Ed
    • Reader's Corner
    • Editorial
  • TV
  • Life
  • Health
  • Environment
  • Travel
  • Food
  • Fashion
  • Science
  • Religion
  • History
  • Feature
  • Expat Corner

COVID-19 mRNA pioneer begins working on pan-coronavirus vaccine

by French Press Agency - AFP

WASHINGTON Sep 10, 2021 - 12:18 pm GMT+3
Pfizer-BioNTech's (L) and Moderna's COVID-19 vaccines, both developed with mRNA technology, sit in baskets at the vaccine clinic at Hartford Hospital in Hartford, Connecticut, U.S., Aug. 24, 2021. (AFP Photo)
Pfizer-BioNTech's (L) and Moderna's COVID-19 vaccines, both developed with mRNA technology, sit in baskets at the vaccine clinic at Hartford Hospital in Hartford, Connecticut, U.S., Aug. 24, 2021. (AFP Photo)
by French Press Agency - AFP Sep 10, 2021 12:18 pm
RECOMMENDED
A meteorite creates a streak of light across the night sky over the North Yorkshire moors at Leaholm, near Whitby, northern England, U.K., April 26, 2015. (Reuters Photo)

Asteroid's near miss highlights blind spots in planetary defenses

space

It has been 16 years since two scientists conducted their research at the University of Pennsylvania that in time would pave the way for billions to be vaccinated against COVID-19, and now the duo has been honored with a $3 million Breakthrough Prize. Drew Weismann, one of the two, surely isn't resting on his laurels though.

The University of Pennsylvania immunologist, who on Thursday shared the $3 million 2022 Breakthrough Prize in Life Sciences with his longtime collaborator Katalin Kariko, is now spearheading efforts to design a new vaccine against all coronaviruses.

The Silicon Valley-backed award honors major discoveries with the highest cash amounts in science.

"There have been three (coronavirus) pandemics or epidemics in the past 20 years," Weissman told Agence France-Presse (AFP) in an interview, referring to the original SARS virus, MERS and COVID-19.

"You have to assume there's going to be more, and our idea was that we could wait for the next coronavirus epidemic or pandemic, and then spend a year and a half making a vaccine. Or we could make one now and have it either ready to go, or use it now."

The 62-year-old and his team started work on the project last spring and have so far published two papers, with promising results.

One of the vaccines was shown to prevent SARS and a few other animal coronaviruses that have the potential to cross into humans.

By now, many are familiar with the basic principles of mRNA (messenger ribonucleic acid) vaccines: They deliver genetic instructions to our cells to build the spike protein of the coronavirus in order to evoke antibodies when our bodies encounter the real virus.

The new focus is to try to train our immune systems to parts of the virus that do not mutate as fast as the spike. These are called "conserved regions."

As a practicing doctor for most of his life, "my dream since starting college and medical school was to make something that helps people," Weissman said, adding it made him "incredibly happy" to see the vaccines he laid the groundwork for save lives.

But while he foresaw the issue of global vaccine inequality – and is working on a project with the Thai government to develop their own COVID-19 vaccine for this reason – he admitted to being astonished by the level of vaccine hesitancy seen in wealthy countries.

"The conservative anti-science, anti-government people completely surprised us. I just didn't expect that group to come out against vaccines," he said.

New applications

While mRNA technology is enjoying widespread attention, Weissman remembers a time when the field was a scientific backwater.

"We started working together in 1998, and that was without much funding and without much in the way of publications," he said of his work with Kariko.

In 2005, they found a way to alter synthetic RNA to stop it from causing a massive inflammatory response found in animal experiments.

"Just before our paper was published I said 'Our phones are going to ring off the hook,'" he recalled.

"We sat there staring at our phones for five years, and they never rang!"

With a second big breakthrough in 2015, they found a new way to deliver the particles safely and effectively to their target cells, using a fatty coating called "lipid nanoparticles."

Both developments are part of the Pfizer-BioNTech and Moderna COVID-19 vaccines today.

Beyond vaccines, mRNA technology is also being heralded for its potential to revolutionize medicine.

Weissman's team is working on using RNA to develop a single-injection gene therapy to overcome the defect that causes sickle cell anemia, a genetic blood disease that 200,000 babies are born with in Africa every year.

Significant technical challenges remain to ensure the treatment is able to correctly edit genes and is safe, but the researchers are hopeful.

Bone marrow transplant, an expensive treatment with serious risks, is currently the only cure.

RECOMMENDED
A meteorite creates a streak of light across the night sky over the North Yorkshire moors at Leaholm, near Whitby, northern England, U.K., April 26, 2015. (Reuters Photo)

Asteroid's near miss highlights blind spots in planetary defenses

space
  • shortlink copied
  • Last Update: Sep 10, 2021 3:18 pm
    RELATED TOPICS
    fight-against-terrorism DEUTSCHE-BANK US-LIBYA-RELATIONS
    KEYWORDS
    covid-19 pandemic mrna covid-19 vaccines coronavirus sars-cov-2
    The Daily Sabah Newsletter
    Keep up to date with what’s happening in Turkey, it’s region and the world.
    You can unsubscribe at any time. By signing up you are agreeing to our Terms of Use and Privacy Policy. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
    A Toyota C-HR Prologue model, which will be manufactured at Toyota Motor Manufacturing Türkiye (TMMT) in the northwestern province of Sakarya, Türkiye. (Courtesy of TMMT)

    Türkiye plant pitched to manufacture new Toyota C-HR plug-in hybrid

    automotive-industry
    A U.S. Air Force airman marshals an F-16 Fighting Falcon aircraft assigned to the 480th Fighter Squadron, at the 86th Air Base near Fetesti, Romania, Feb. 17, 2022. (Reuters Photo)

    Türkiye warns of 'price' if US fails to deliver long-sought fighter jets

    F-16-FIGHTER-JETS

    Pilot dead, other pilot missing after Greek F-4 jet crashes

    Greece

    Finland probing Paludan's links with Russia: FM Haavisto

    nato-membership
    No Image
    Nature blooms as spring hits off
    PHOTOGALLERY
    • POLITICS
    • Diplomacy
    • Legislation
    • War On Terror
    • EU Affairs
    • News Analysis
    • TÜRKİYE
    • Istanbul
    • Education
    • Investigations
    • Minorities
    • Diaspora
    • World
    • Mid-East
    • Europe
    • Americas
    • Asia Pacific
    • Africa
    • Syrian Crisis
    • İslamophobia
    • Business
    • Automotive
    • Economy
    • Energy
    • Finance
    • Tourism
    • Tech
    • Defense
    • Transportation
    • News Analysis
    • Lifestyle
    • Health
    • Environment
    • Travel
    • Food
    • Fashion
    • Science
    • Religion
    • History
    • Feature
    • Expat Corner
    • Arts
    • Cinema
    • Music
    • Events
    • Portrait
    • Performing Arts
    • Reviews
    • Sports
    • Football
    • Basketball
    • Motorsports
    • Tennis
    • Opinion
    • Columns
    • Op-Ed
    • Reader's Corner
    • Editorial
    • Photo gallery
    • Jobs
    • privacy
    • about us
    • contact us
    • RSS
    © Turkuvaz Haberleşme ve Yayıncılık 2021